2016 is the year of China's "13th Five-Year Plan", and it is also the period when genetic sequencing is "prosperous". Whether it is market or policy, gene sequencing is in the outbreak stage in China. In recent years, the state has continuously introduced policies to encourage the development of gene sequencing, and new types of companies are constantly entering the market. This paper combines the data released by the China Investment Consulting Industry Research Center and Huachuang Securities to introduce the current market development and domestic distribution of gene sequencing.
$16 billion market outbreak
With the continuous upgrading of technology and the continuous maturity of technology applications, the scale of the gene sequencing market has been continuously expanded. According to statistics from the China Investment Consulting Industry Research Center, the global gene sequencing market has grown at a rate of 20% over the past five years. The overall growth rate of the industry will remain at around 18% in the next five years. By 2020, the global gene sequencing market will be large. Up to $16 billion.
China and developed countries are at the same starting line in terms of genetic technology. The China Investment Consulting Industry Research Center predicts that the awareness of the importance of genetic testing in China will continue to increase in the next five years, with a potential demand of about 300 million people.
Gene sequencing has a broad market space. China is currently divided into four directions, namely genetic disease diagnosis, prenatal screening and diagnosis, preimplantation embryo genetic diagnosis and tumor diagnosis and treatment.
Non-invasive prenatal screening is a relatively mature field of gene sequencing applications. In recent years, with the introduction of a series of national policies to promote gene sequencing technology, non-invasive prenatal screening has ushered in market recognition and prices are gradually decreasing. From the pricing policy of non-invasive prenatal genetic testing in some provinces in China in the past two years, non-invasive prenatal screening below 1,000 yuan is expected to be realized.
Preimplantation genetic diagnosis is another promising field of application for gene sequencing. In recent years, with the increasing rate of infertility, and the liberalization of China's second-child policy, pre-implantation genetic diagnosis has a large market space. Huachuang Securities has counted 1-2 cells from the blastomere on the third day of in vitro fertilization or 3-10 trophoblast cells on the 5th day of the blastocyst for genetic analysis and primary cell detection. The cost ranges from 2000-3000 yuan, and there are 1.3-156 million pairs of couples performing assisted reproductive surgery each year. Assuming that 30% of these couples are willing to perform preimplantation genetic diagnosis, the market size in this field is about 10 billion. yuan.
China is a country with high cancer incidence, so the personalized treatment of cancer also contains a larger market for gene sequencing. Today, there are also many companies in the Chinese market engaged in research on tumor genetic testing, and the competition is becoming more and more fierce.
1.NMN, full name Beta Nicotinamide Mononucleotide, designed to reverse the signs of aging in the body.
Our production method of NMN is Enzymatic, while purity up to 99.5%, report from third lab in US is available.
It be widely used in the market as powder, capsules and tablets.
2. Function of NMN:
Nicotinamide mononucleotide(NMN) in human cells play an important role in energy generation, it involved in intracellular NAD (nicotinamide adenine dinucleotide, cell energy conversion important coenzyme) synthesis, used in anti-aging, fall blood sugar and other health care products.
Nmn Powder,Nmn Supplements,Nmn Powder Pharmaceutical Grade,Food Grade Nmn
Xi'an Natural Field Bio-Technique Co., Ltd. , https://www.natural-field.com